Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Total Non-Current Liabilities (2019 - 2025)

Biodesix (BDSX) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $72.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 16.85% year-over-year to $72.5 million, compared with a TTM value of $72.5 million through Dec 2025, up 16.85%, and an annual FY2025 reading of $72.5 million, up 16.85% over the prior year.
  • Total Non-Current Liabilities was $72.5 million for Q4 2025 at Biodesix, roughly flat from $72.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $72.5 million in Q4 2025 and bottomed at $24.1 million in Q1 2022.
  • Average Total Non-Current Liabilities over 5 years is $54.3 million, with a median of $58.9 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities plummeted 61.77% in 2022, then surged 125.05% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $27.4 million in 2021, then skyrocketed by 80.45% to $49.5 million in 2022, then increased by 23.53% to $61.1 million in 2023, then increased by 1.56% to $62.1 million in 2024, then increased by 16.85% to $72.5 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for BDSX at $72.5 million in Q4 2025, $72.3 million in Q3 2025, and $71.4 million in Q2 2025.